Vitrolife AB (publ) - Fourth quarter and full year report 2025

Core Insights - Vitrolife AB reported a significant decline in net income for the fourth quarter and full year, primarily due to an impairment charge of SEK 5,357 million [4][4][4] Fourth Quarter Summary - Sales amounted to SEK 891 million, reflecting a 7% decrease in SEK and a 6% organic growth in local currencies excluding discontinued business [4] - Regional sales performance showed a -1% change in EMEA, +9% in Americas, and +10% in APAC [4] - Product group sales growth in local currencies was +10% in Consumables, +6% in Technologies, and +1% in Genetics [4] - Gross margin decreased to 58.0% from 61.1% [4] - EBITDA was SEK 196 million, with an EBITDA margin of 22.0%, down from 35.1% [4] - Net income was reported at SEK -5,314 million, resulting in earnings per share of SEK -39.24 [4] - Operating cash flow for the quarter was SEK 160 million [4] Full Year Summary - Total sales for the year were SEK 3,440 million, a 5% decrease in SEK and a 4% organic growth in local currencies excluding discontinued business [4] - Regional sales performance included +5% in EMEA, +8% in Americas, and -1% in APAC [4] - Product group sales growth in local currencies was +8% in Consumables, +1% in Technologies, and +3% in Genetics [4] - Gross margin for the year decreased to 58.1% from 59.3% [4] - EBITDA for the year was SEK 949 million, with an EBITDA margin of 27.6%, down from 34.0% [4] - Net income for the year was SEK -5,013 million, resulting in earnings per share of SEK -37.01 [4] - Operating cash flow for the year was SEK 635 million [4] Dividend Proposal - The Board proposed a dividend of SEK 149 million, corresponding to SEK 1.10 per share, unchanged from the previous year [4]